Extracts of a report from the Rapid C-19 Oversight Group, titled Rapid C-19 Report to CMO: Tixagevimab plus Cilgavimab (Evusheld, AZD7442; AstraZeneca) in Pre-Exposure Prophylaxis, dated 24/08/2022.
Module 4 adduced:
• Pages 1, 6-8, 10-12 and 16 on 30 January 2025